CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01229943
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:33.186665+00:00
Published At: 2016-02-11T00:00:00+00:00
Record Updated At: 2022-08-04
Results Posted At: 2016-02-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Pancreatic Neuroendocrine Tumor", "Locally Advanced Pancreatic Neuroendocrine Tumor", "Pancreatic Gastrinoma", "Pancreatic Neuroendocrine Tumor G1", "Pancreatic Neuroendocrine Tumor G2", "Pancreatic Vipoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-08-04"
protocolSection.identificationModule.nctId: "NCT01229943"
protocolSection.identificationModule.officialTitle: "Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2016-02-11"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.